Cancer Stem Cell News Volume 11.03 | Jan 26 2022

    0
    38







    2022-01-26 | CSCN 11.03


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.03 – 26 January, 2022
    TOP STORY

    Different Pancreatic Cancer Microenvironments Convert iPSCs into Cancer Stem Cells Exhibiting Distinct Plasticity with Altered Gene Expression of Metabolic Pathways

    The isolated cells were characterized for cancer stem cell characteristics in vitro and in vivo as well as their responses to anticancer drugs.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    Register now for the 5th DNA Repair/Replication Structures and Cancer Conference.
    PUBLICATIONSRanked by the impact factor of the journal

    RICH1 Inhibits Breast Cancer Stem Cell Traits through Activating Kinases Cascade of Hippo Signaling by Competing with Merlin for Binding to Amot-p80

    Scientists found that the low expression of RICH1 in breast cancer was associated with poor prognosis. Depletion of RICH1 promoted the stemness and disrupted the normal epithelial architecture of MCF10A cells.
    [Cell Death & Disease]

    Full Article

    The Association between Bromodomain (BrD) Proteins and Cancer Stemness in Different Solid Tumor Types

    Researchers demonstrated that significant upregulation of ATAD2 and SMARCA4, and downregulation of SMARCA2 was consistently associated with enriched CSC-like phenotype, respectively.
    [International Journal of Cancer]

    Abstract

    KRT13 Promotes Stemness and Drives Metastasis in Breast Cancer through a Plakoglobin/C-myc Signaling Pathway

    Keratin 13 (KRT13) plays an important role in breast cancer progression and metastasis. The authors elucidated the mechanism by which KRTs promoted breast cancer growth and metastasis.
    [Breast Cancer Research]

    Full Article

    Estrogen Receptor Beta Increases Clear Cell Renal Cell Carcinoma Stem Cell Phenotype via Altering the circPHACTR4/miR-34b-5p/C-myc Signaling

    Scientists found estrogen receptor beta could increase the CSC population via altering the circPHACTR4/miR-34b-5p/c-Myc signaling.
    [FASEB Journal]

    AbstractFull Article

    Tumor Radioresistance Caused by Radiation-Induced Changes of Stem-Like Cell Content and Sub-lethal Damage Repair Capability

    Four types of human oral squamous carcinoma cell lines, non-radioresistant cell lines, and radioresistant cell lines, were used to measure the surviving fraction after single-dose irradiation, split-dose irradiation, and multi-fractionated irradiation.
    [Scientific Reports]

    Full Article

    Tanshinone IIA Attenuates the Stemness of Breast Cancer Cells via Targeting the miR-125b/STARD13 Axis

    In vitro mammary spheroid formation, flow cytometry assay on CD24−/CD44+ sub-population, ALDH activity detection, cell viability assay and western blot analysis, and in vivo tumor-initiating analysis were performed to examine the effects of Tanshinone IIA on the stemness of breast cancer cells.
    [Experimental Hematology & Oncology]

    Full Article

    SETD5 Regulates Glycolysis in Breast Cancer Stem-Like Cells and Fuels Tumor Growth

    Downregulation of SET-domain containing 5 (SETD5) significantly decreased breast cancer stem-like cells properties and glycolysis in vitro and in vivo.
    [American Journal of Pathology]

    Abstract

    Deregulation of the CD44-NANOG-MDR1 Associated Chemoresistance Pathways of Breast Cancer Stem Cells Potentiates the Anti-cancer Effect of Kaempferol in Synergism with Verapamil

    Researchers used Kaempferol in combination with Verapamil, in multiple assays to determine if there was an inhibitory effect on breast CSCs.
    [Toxicology and Applied Pharmacology]

    AbstractGraphical Abstract

    FOXM1 Mediates GDF-15 Dependent Stemness and Intrinsic Drug Resistance in Breast Cancer

    The expressions and interactions of GDF-15, FOXM1, and stemness (OCT4 and SOX2), and drug resistance (ABCC5) markers were evaluated in breast cancer.
    [Molecular Biology Reports]

    Abstract

    Tumors Are 3D. Shouldn't Your In Vitro Model Be? Learn More.
    REVIEWS

    Mechanisms of Polycomb Group Protein Function in Cancer

    Cancer arises from a multitude of disorders resulting in loss of differentiation and a stem cell-like phenotype characterized by uncontrolled growth. Polycomb Group proteins are members of multiprotein complexes that are highly conserved throughout evolution.
    [Cell Research]

    Full Article

    INDUSTRY AND POLICY NEWS

    Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

    Lyell Immunopharma, Inc. announced that US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.
    [Lyell Immunopharma, Inc. (Globenewswire, Inc.)]

    Press Release

    OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

    OSE Immunotherapeutics SA announced that the Japanese Patent Office has issued the notice of allowance for a new patent covering Tedopi®, a combination of neoepitopes, for use after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients.
    [OSE Immunotherapeutics SA]

    Press Release

    FEATURED EVENT

    Cell Therapy Analytics Symposium

    2 March, 2022
    Online

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scholar – Tumor Immunology

    Moffit Cancer Center – Tampa Bay, Florida, United States

    PhD Student – Chronic Lymphocytic Leukemia

    Luxembourg Institute of Health – Luxembourg, Luxembourg

    Postdoctoral Research Fellow – Genetic Alterations in Prostate Cancer

    Wayne State University School of Medicine – Detroit, Michigan, United States

    Postdoctoral Research Associate – Drug Responses in Glioblastoma

    Queen Mary University of London – London, England, United Kingdom

    Postdoctoral Research Associate – Tumor Stem Cells

    Queen Mary University of London – London, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter